Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency

doi:10.1016/0021-9150(91)90211-K

Atherosclerosis

Volume 86, Issues 2–3, February 1991, Pages 153-161

https://doi.org/10.1016/0021-9150(91)90211-K Get rights and content

Abstract

We have recently established that low density lipoprotein (LDL) of most patients with coronary atherosclerosis differs from the LDL of most healthy subjects by its ability to cause primary atherosclerotic changes, i.e. the accumulation of intracellular cholesterol in the cells of smooth muscle origin cultured from unaffected intima of human aorta. Patients' LDL has a 2.5–5-fold lower content of sialic acid as compared with the LDL of healthy subjects. On the other hand, desialylation of native LDL with neuraminidase makes it capable of causing accumulation of intracellular cholesterol similar to patients' LDL. In the present study we showed that LDL of patients and healthy donors did not differ in the content and composition of protein and lipids. Thus, the difference in the content of sialic acid is the only difference observed between atherogenic LDL of patients and nonatherogenic LDL of healthy donors. A low content of sialic acid is characteristic of both protein and lipid moiety of LDL particle. Sialic acid content was determined in individual LDL preparations obtained from patients and healthy donors. The sialic acid of LDL preparations of 25 out of 27 patients was below 18 μg/mg protein. LDL from 2 patients with higher sialic acid content proved to be normal. The ability of patients' LDL and LDL desialylated with neuraminidase in vitro to cause the accumulation of intracellular lipids correlated with the degree of lipoprotein desialyation. Apparently, the ability of patients' LDL to stimulate the cellular lipid accumulation may be explained by a deficiency of sialic acid in the lipoprotein particle.

References (36)

V.V. Tertov et al.
Low density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells
Exp. Mol. Pathol.
(1989)
A.N. Orekhov et al.
Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells. Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients
Biochem. Biophys. Res. Commun.
(1989)
V.V. Tertov et al.
Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins
Biochem. Biophys. Res. Commun.
(1989)
E.I. Chazov et al.
Atherogenicity of blood serum from patients with coronary heart disease
Lancet
(1986)
J. Folch et al.
A simple method for the isolation and purification of total lipids from animal tissues
J. Biol. Chem.
(1957)
L. Warren
The thiobarbituric acid assay of sialic acids
J. Biol. Chem.
(1959)
O.H. Lowry et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951)
K. Yagi
Lipid peroxidation. Assay for blood plasma and serum
Methods Enzymol.
(1984)
J.W. Gaubatz et al.
Quantitation, isolation, and characterization of human lipoprotein[a]
Methods Enzymol.
(1986)
J.L. Goldstein et al.
Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339
J. Biol. Chem.
(1975)

A.N. Orekhov et al.

Lipids in cells of atherosclerotic and uninvolved human aorta. II. Lipid metabolism in primary culture

Exp. Mol. Pathol.

(1985)

I. Filipovic et al.

Role of net charge of low density lipoproteins in high affinity binding and uptake by cultured cells

Biochem. Biophys. Res. Commun.

(1979)

M.E. Haberland et al.

The role of altered lipoproteins in the pathogenesis of atherosclerosis

Am. Heart J.

(1987)

K.H. Weisgraber et al.

Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts

J. Biol. Chem.

(1978)

A.N. Orekhov et al.

Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low density lipoproteins and an approach to its elimination

Circ. Res.

(1988)

A.N. Orekhov et al.

Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells

Circ. Res.

(1990)

L. Campeau

Grading of angina pectoris

Circulation

(1976)

F.T. Lindgren

Preparative ultracentrifugal laboratory procedures and suggestions for lipoprotein analysis

Cited by (117)

The role of protein glycosylation in the occurrence and outcome of acute ischemic stroke
2023, Pharmacological Research
Acute ischemic stroke (AIS) is a serious and life-threatening disease worldwide. Despite thrombolysis or endovascular thrombectomy, a sizeable fraction of patients with AIS have adverse clinical outcomes. In addition, existing secondary prevention strategies with antiplatelet and anticoagulant drugs therapy are not able to adequately decrease the risk of ischemic stroke recurrence. Thus, exploring novel mechanisms for doing so represents an urgent need for the prevention and treatment of AIS. Recent studies have discovered that protein glycosylation plays a critical role in the occurrence and outcome of AIS. As a common co- and post-translational modification, protein glycosylation participates in a wide variety of physiological and pathological processes by regulating the activity and function of proteins or enzymes. Protein glycosylation is involved in two causes of cerebral emboli in ischemic stroke: atherosclerosis and atrial fibrillation. Following ischemic stroke, the level of brain protein glycosylation becomes dynamically regulated, which significantly affects stroke outcome through influencing inflammatory response, excitotoxicity, neuronal apoptosis, and blood-brain barrier disruption. Drugs targeting glycosylation in the occurrence and progression of stroke may represent a novel therapeutic idea. In this review, we focus on possible perspectives about how glycosylation affects the occurrence and outcome of AIS. We then propose the potential of glycosylation as a therapeutic drug target and prognostic marker for AIS patients in the future.
Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties
2019, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Citation Excerpt :
Moreover, atherogenic immune complexes present in the circulation contain LDL that display modifications similar to those found in desialylated LDL [14]. When administered to a primary culture of human aortic intimal cells or to a culture of human monocyte-derived macrophages, desialylated LDL induce intracellular cholesterol accumulation [10,13,15,16]. Native LDL desialylated with neuraminidase in vitro reveal similar biological activity [17,18].
Human plasma lipoproteins are known to contain various glycan structures whose composition and functional importance are starting to be recognized. We assessed N-glycosylation of human plasma HDL and LDL and the role of their glycomes in cellular cholesterol metabolism.
N-glycomic profiles of native and neuraminidase-treated HDL and LDL were obtained using HILIC-UHPLC-FLD. Relative abundance of the individual chromatographic peaks was quantitatively expressed as a percentage of total integrated area and N-glycan structures present in each peak were elucidated by MALDI-TOF MS. The capacity of HDL to mediate cellular efflux of cholesterol and the capacity of LDL to induce cellular accumulation of cholesteryl esters were evaluated in THP-1 cells.
HILIC-UHPLC-FLD analysis of HDL and LDL N-glycans released by PNGase F resulted in 22 and 18 distinct chromatographic peaks, respectively. The majority of N-glycans present in HDL (~70%) and LDL (~60%) were sialylated with one or two sialic acid residues. The most abundant N-glycan structure in both HDL and LDL was a complex type biantennary N-glycan with one sialic acid (A2G2S1). Relative abundances of several N-glycan structures were dramatically altered by the neuraminidase treatment, which selectively removed sialic acid residues. Native HDL displayed significantly greater efficacy in removing cellular cholesterol from THP-1 cells as compared to desialylated HDL (p < 0.05). Cellular accumulation of cholesteryl esters in THP-1 cells was significantly higher after incubations with desialylated LDL particles as compared to native LDL (p < 0.05).
N-glycome of human plasma lipoproteins reveals a high level of diversity, which directly impacts functional properties of the lipoproteins.
Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice
2018, Journal of Biological Chemistry
Atherosclerosis is a complex disease that involves alterations in lipoprotein metabolism and inflammation. Protein and lipid glycosylation events, such as sialylation, contribute to the development of atherosclerosis and are regulated by specific glycosidases, including sialidases. To evaluate the effect of the sialidase neuraminidase 1 (NEU1) on atherogenesis, here we generated apolipoprotein E (ApoE)-deficient mice that express hypomorphic levels of NEU1 (Neu1^hypoApoe^−/−). We found that the hypomorphic NEU1 expression in male Apoe^−/− mice reduces serum levels of very-low-density lipoprotein (VLDL) and LDL cholesterol, diminishes infiltration of inflammatory cells into lesions, and decreases aortic sinus atherosclerosis. Transplantation of Apoe^−/− bone marrow (BM) into Neu1^hypoApoe^−/− mice significantly increased atherosclerotic lesion development and had no effect on serum lipoprotein levels. Moreover, Neu1^hypoApoe^−/− mice exhibited a reduction in circulating monocyte and neutrophil levels and had reduced hyaluronic acid and P-selectin adhesion capability on monocytes/neutrophils and T cells. Consistent with these findings, administration of a sialidase inhibitor, 2-deoxy-2,3-dehydro-N-acetylneuraminic acid, had a significant anti-atherogenic effect in the Apoe^−/− mice. In summary, the reduction in NEU1 expression or function decreases atherosclerosis in mice via its significant effects on lipid metabolism and inflammatory processes. We conclude that NEU1 may represent a promising target for managing atherosclerosis.
Circulating desialylated low density lipoprotein
2017, Cor et Vasa
Citation Excerpt :
What is the reason for LDL atherogenicity? Comparison of atherogenic and non-atherogenic LDL properties demonstrated a significant difference in the sialic acid content of lipoprotein particles [23,24]. Sialic acid is a terminal monosaccharide of asparagine-bound biantennary carbohydrate chains within LDL glycoconjugate moiety.
Accumulation of lipids is the central event in the development of atherosclerotic lesion. Circulating low-density lipoprotein (LDL) particles are known to be the major source of cholesterol and other lipids stored in atherosclerotic plaque. However, not all LDL particles possess atherogenic properties. In order to induce lipid accumulation in arterial cells, LDL particles have to undergo modifications. Although among such modifications the oxidation remains the most studied one, other atherogenic LDL modifications have been described. According to a series of studies conducted with blood serum and LDL from atherosclerotic patients, desialylation is one of the earliest if not the first atherogenic modification of LDL. Desialylation occurs in the bloodstream and is followed by a cascade of other modifications, including the reduction of LDL particle size and increase of its density, acquisition of negative electrical charge, oxidation and formation of highly atherogenic complexes. In this mini-review we will discuss the concept of multiple atherogenic modification of LDL leading to initiation and progression of atherosclerosis.
Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study
2024, Journal of Pharmacology and Experimental Therapeutics
Atherosclerosis and Its Related Laboratory Biomarkers
2023, International Journal of Molecular Sciences

View all citing articles on Scopus

View full text

Research paperDesialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency

Abstract

Exp. Mol. Pathol.

Biochem. Biophys. Res. Commun.

Biochem. Biophys. Res. Commun.

Lancet

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Methods Enzymol.

Methods Enzymol.

J. Biol. Chem.

Exp. Mol. Pathol.

Biochem. Biophys. Res. Commun.

Am. Heart J.

J. Biol. Chem.

Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low density lipoproteins and an approach to its elimination

Circ. Res.

Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells

Circ. Res.

Grading of angina pectoris

Circulation

Preparative ultracentrifugal laboratory procedures and suggestions for lipoprotein analysis

Research paper
Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency